Browse the evidence

The hepatic lipase (HL) promoter polymorphism (HL-514T allele) modulates the effect of physical activity on HDL-C levels, with carriers of the T allele showing a blunted response to exercise-induced HDL increases.

If you have certain genetic variants (HL-514T), you might not see as big a boost in 'good' cholesterol (HDL) from exercise as others. This doesn't mean exercise is useless, but it suggests you might need a more targeted approach to managing heart disease risk.

The dual agonist I-M-150847 facilitates rapid redistribution and recycling of GLP-1 receptors to the plasma membrane, maintaining them in a sensitized state, unlike monoagonists which cause prolonged internalization.

This mechanism explains why dual agonists might work better: they keep the insulin-stimulating receptors 'ready' on the cell surface rather than hiding them inside the cell for long periods. This is a molecular detail relevant to drug developers.

Bypassing or modifying the small intestine (via surgery or endoscopy) induces type 2 diabetes remission and improves glycemic control, independent of weight loss alone.

If you have obesity and Type 2 Diabetes, standard weight loss might not be enough. Modern endoscopic procedures that target the small intestine (like bypass liners or mucosal resurfacing) can induce diabetes remission and improve blood sugar control, often with less risk than traditional surgery. However, these are complex treatments requiring a multidisciplinary team to select the right procedure for your specific body type and ethnicity.

Medicare-aged adults (65-69) with obesity but without Type 2 Diabetes have significantly lower prescribing and dispensing rates of anti-obesity GLP-1 receptor agonists compared to adults aged 60-64, likely due to Medicare's prohibition on covering these medications.

If you are over 65 and have obesity but no diabetes, you may face significant barriers to accessing GLP-1 medications like Wegovy or Zepbound because Medicare currently prohibits coverage for these specific anti-obesity drugs. This results in significantly lower prescribing and filling rates compared to those aged 60-64. Consult your provider about available options, but be aware that cost and coverage restrictions may limit your access to these specific hormonal treatments.

Patients who use anti-obesity medications (AOMs) prior to surgery experience significant weight regain (average 18 kg) upon discontinuation, yet this experience does not change their expectation of weight loss from surgery.

If you stop taking weight loss drugs, you will likely regain most of the weight you lost (average 18kg). This is common. However, this experience does not mean you are destined to fail surgery. Many patients use surgery to achieve greater weight loss than drugs alone, and some even use drugs after surgery to enhance results.

Administration of the chimeric multi-agonist peptide GEP44 reduces body weight and energy intake in diet-induced obese mice primarily through a GLP-1 receptor (GLP-1R) dependent mechanism.

This research indicates that a new peptide drug called GEP44 can help reduce body weight and food intake in obese mice by targeting specific receptors in the brain. The effects rely heavily on the GLP-1 receptor, similar to drugs like Ozempic or Wegovy, but GEP44 also targets other receptors (Y1 and Y2). While promising in mice, this is preprint research and not yet available for human use.

Roux-en-Y gastric bypass (RYGB) surgery increases glycemic variability and time in hypoglycemic ranges in both diabetic and non-diabetic patients within six months post-operation, with non-diabetic patients showing a significant decrease in time in range due to increased hypoglycemia.

If you undergo Roux-en-Y gastric bypass, expect your blood sugar to fluctuate more, including episodes of low blood sugar (hypoglycemia), even if you did not have diabetes before. This happens because the surgery speeds up how food enters your intestine. Use a continuous glucose monitor to track these changes, as standard HbA1c tests might miss these dangerous lows.

Off-label use of generic medications (e.g., metformin, SGLT2 inhibitors) or compounded GLP-1 agonists carries risks of unknown efficacy, safety issues, and potential adverse events compared to FDA-approved anti-obesity medications.

Avoid compounded or off-label obesity medications. They are not regulated for safety or efficacy and may contain unapproved ingredients. Talk to your doctor about FDA-approved options, even if they are expensive, as they are the only ones proven safe and effective.

Use of GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide, dulaglutide) for weight loss is associated with an emerging adverse effect of alopecia, primarily presenting as telogen effluvium or androgenetic alopecia.

If you are using a GLP-1 medication for weight loss and notice increased hair shedding, do not immediately stop the medication. This is a reported side effect, often presenting as temporary shedding (telogen effluvium) linked to metabolic stress or rapid weight loss. Consult a dermatologist to confirm the type of hair loss; it may be manageable without discontinuing your weight loss treatment.

Obesity is a disease of the ponderostat characterized by a dysregulated neuroendocrine set point that actively defends a higher body weight through compensatory reductions in energy expenditure and increases in appetite.

Recognize that obesity involves a biological set point that resists change. Simple calorie counting often fails because the body compensates by lowering metabolism and increasing hunger. Effective management may require addressing these biological drivers, potentially through pharmacological treatments that target the ponderostat, rather than relying solely on willpower.

Use of GLP-1 receptor agonists (GLP-1RAs) is associated with a significantly increased risk of developing alopecia, specifically androgenetic alopecia (AGA), across multiple agents including semaglutide, tirzepatide, dulaglutide, liraglutide, and exenatide.

If you are using a GLP-1RA (like semaglutide or tirzepatide), be aware that there is a statistically significant, though small, increased risk of hair thinning (androgenetic alopecia). This risk varies by drug; tirzepatide did not show this risk in this study, while semaglutide, dulaglutide, and liraglutide did. The risk is not universal, and it does not appear to affect Alopecia Areata. Discuss this with your provider, especially if you have a family history of hair loss, as the mechanism may be related to metabolic changes or rapid weight loss rather than the drug itself.

Tirzepatide use is associated with a very low absolute risk of acute pancreatitis (<1%), and when cases occur, they are typically mild and confounded by traditional etiologies such as gallstones or alcohol.

If you are taking tirzepatide, be aware that pancreatitis is a known but rare side effect (<1% risk). Most cases are mild and often linked to other factors like gallstones. Report severe abdominal pain to your doctor immediately, but do not let fear of this rare event prevent you from using a medication that effectively manages weight and blood sugar.

Tirzepatide, a dual GLP-1/GIP agonist, demonstrates significant neuroprotective effects against neurodegenerative diseases (Alzheimer's, Parkinson's) and cerebrovascular events, outperforming semaglutide due to its dual-action mechanism.

If you have Type 2 Diabetes or Obesity, discuss with your doctor whether GLP-1/GIP agonists like Tirzepatide might offer neuroprotective benefits beyond weight loss, especially if you have a family history of dementia or cognitive decline. Tirzepatide may be superior to Semaglutide for brain health due to its dual mechanism.

Perioperative use of GLP-1 receptor agonists in obese patients undergoing total hip arthroplasty significantly reduces the incidence of periprosthetic joint infection and 90-day hospital readmissions.

If you are obese and scheduled for hip replacement, ask your surgeon about continuing or starting GLP-1 agonists (like semaglutide) up to 3 months before surgery. This may lower your risk of infection and hospital readmission without increasing other complications.

Tirzepatide does not demonstrate a disproportionate risk of gynecological hemorrhagic events compared to semaglutide in real-world post-marketing surveillance.

If you are using tirzepatide and experience menstrual changes, know that current large-scale data shows your risk of bleeding is statistically similar to those using semaglutide. High consumer reporting on social media may inflate the perception of risk, but clinical evidence does not support a unique safety signal for tirzepatide regarding gynecological hemorrhage.

Off-label use of semaglutide (Ozempic) for aesthetic weight loss in non-diabetic individuals causes therapeutic exclusion for Type 2 Diabetes patients due to supply shortages.

If you are using Ozempic off-label, be aware that your demand contributes to shortages for diabetics. Consider using approved alternatives like Wegovy if available, or prioritize lifestyle changes to reduce pressure on the supply chain for those who medically need it.

Rapid weight loss induced by semaglutide causes 'Ozempic Face' and 'Ozempic Butt' due to the skin's inability to shrink at the same rate as fat loss.

If you are using semaglutide, expect potential skin laxity, especially in the face and buttocks. Slower weight loss allows skin to adapt; rapid loss may result in sagging. Consider consulting a dermatologist for skin-tightening options if this is a major concern.

Discontinuation of semaglutide leads to significant weight regain (rebound effect) and psychological distress due to the dissipation of hormonal effects.

If you stop semaglutide, expect significant weight regain and increased hunger. Plan for a gradual taper and lifestyle changes to maintain weight. Psychological support may be needed to manage the rebound effect.

Neutralization of the chemokine CXCL10 prevents high-fat diet-induced skeletal muscle atrophy and inflammation in mice.

This research suggests that in states of high metabolic stress (like high-fat diets), muscle loss is driven by specific inflammatory signals (CXCL10). While this is a mouse study, it implies that managing systemic inflammation might be as important as exercise for preserving muscle mass during weight loss or obesity.

Unimolecular GLP-1/Apelin hybrid peptides (specifically ELA, ELA-Lys12, and ELA-Lys38) cause prominent appetite suppression in mice without inducing malaise, with effects lasting up to 42 hours for the base peptide and 63 hours for acylated forms.

This research suggests that combining GLP-1 and Apelin pathways in a single peptide molecule can effectively reduce food intake for extended periods (up to 63 hours with acylation) without causing the nausea often seen with current GLP-1 drugs. While promising in mice, this is pre-clinical data and not yet a human treatment option.

GLP-1/Apelin hybrid peptides (ELA, ELA-Lys12, ELA-Lys38) significantly improve glucose tolerance and insulin secretion in both lean and high-fat-fed mice, with effects lasting up to 21 hours for acylated forms.

These hybrid peptides effectively lower blood glucose levels in mice for up to 21 hours, outperforming single-target approaches in duration. This suggests potential for less frequent dosing in diabetes management, though human trials are required.

GLP-1/Apelin hybrid peptides enhance beta-cell proliferation and protect against cytokine-induced apoptosis, contributing to beta-cell survival.

These hybrid peptides show promise in protecting beta-cells from stress and promoting their growth in laboratory settings. This could translate to better long-term diabetes management by preserving the body's natural insulin production capacity.

GIP receptor (GIPR) agonism suppresses inflammation-induced conditioned taste avoidance (aversion) by attenuating the activity of parabrachial CGRP neurons, while simultaneously enhancing inflammation-induced anorexia via distinct dorsal vagal complex (DVC) circuits.

If you are experiencing sickness-induced nausea and loss of appetite, standard anti-nausea drugs might not stop the feeling of aversion, and standard anti-inflammatories might not stop the nausea. This research suggests that GIP-based therapies could specifically target the 'sickness feeling' (aversion) via brain circuits, potentially allowing patients to feel better without necessarily worsening their lack of appetite, though it does increase food suppression. This is currently experimental in mice.

Tirzepatide use is associated with a significantly increased risk of gastrointestinal adverse events (GIAEs), with nausea and diarrhea being the most frequent, and eructation and impaired gastric emptying showing the highest disproportionality.

If you start tirzepatide, expect gastrointestinal side effects like nausea or diarrhea, especially in the first few months. The risk is higher if you are male, over 65, have Type 2 Diabetes, or take other medications. Working with your doctor to start with a low dose and increase it slowly can help your body adjust and reduce these side effects.